Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1996-08-28
1999-03-02
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514220, A61K 3155
Patent
active
058771735
ABSTRACT:
A method for reducing progressive neuronal degeneration due to Alzheimer's disease is disclosed wherein a neuroprotective drug selected from the group consisting of clozapine, olanzapine and fluperlapine, and salts, isomers and analogs thereof, is administered.
REFERENCES:
patent: 5034400 (1991-07-01), Olney et al.
Olney et al., Archives of Neurology (54), p. 1234. Oct. 1997.
Corso et al., Brain Research (752) p. 1. Mar. 1997.
Satterlee et al., Psychopharmacology Bulletin 31(3), May-Jun. 1995, 534.
Corey-Bloom, J., et al, "Adjunctive therapy in patients with Alzheimer's disease: A practical approach," Drugs Aging 7: 79-87 (1995).
Gong, C.X., et al, "Inhibition of protein phosphatase-2B (calcineurin) activity towards Alzheimer abnormally phosphorylated tau by neuroleptics," Brain Res 741: 95-102 (1996).
Grossberg, G.T., et al, "The older patient with psychotic symptoms," Psychiatr Serv 46: 55-9 (1995).
Niizato, K., et al, "Long-term antipsychotic medication of schizophrenics does not promote the development of Alzheimer's disease brain pathology," J Neurol Sci 138:165-7 (1996).
Rabins, P.V., "Developing treatment guidelines for Alzheimer's disease and other dementias," J Clin Psychiatry 57 Suppl. 14: 37-38 (1996).
Schneider, L.S., "New therapeutic approaches to Alzheimer's disease," J Clin Psychiatry 57 Suppl. 14:30-36 (1996).
Siegal, A., et al, "Discussion: Clinical developments in Alzheimer's disease," J Clin Psychiatry 57 Suppl. 14: 39-44 (1996).
Sunderland, T., "Treatment of the elderly suffering from psychosis and dementia," J Clin Psychiatry 57 Suppl. 9: 53-6 (1996).
Tueth, M.J., "How to manage depression and psychosis in Alzheimer's disease," Geriatrics 50: 43-6, 49 (1995).
Zayas, E.M., et al, "Treating the agitated Alzheimer patient," J Clin Psychiatry 57 Suppl. 7: 46-54 (1996).
Abramowicz, M., "Donepezil (Aricept) for Alzheimer's Disease," The Medical Letter 39: 53-54 (1997).
Bryson, H.M., et al, "Donepezil," Drugs and Aging 10: 234-241 (1997).
Ditzler, K., "Efficacy and Tolerability of Memantine in Patients with Dementia Syndrome," Arzneim.-Forsch./Drug Res. 41 (II) : 773-780 (1991).
Ellison, G., "The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias," Brain Research Reviews 20: 250-267 (1995).
Gilman, S., "Alzheimer's Disease," Perspectives in Biology and Medicine 40: 230-245 (1995).
Gortelmeyer, R., et al, "Memantine in the Treatment of Mild to Moderate Dementia Syndrome," Arzneim.-Forsch./Drug Res. 42: (II) : 904-913 (1992).
Khachaturian, Z.S., "Scientific Opportunities for Developing Treatments for Alzheimer's Disease: Proceedings of Research Planning Workshop 1," Neurobiology of Aging 15, Suppl 2: S11-S15 (1994).
Marx, J., "Searching for Drugs That Combat Alzheimer's," Science 273: 50-53 (1996).
Mattson, M.P., "Degenerative and Protective Signaling Mechanisms in the Neurofibrillary Pathology of AD," Neurobiology of Aging 16: 447-457 (1995).
Olney, J.W., et al, "NMDA antagonist neurotoxicity: Mechanism and prevention," Science 254: 1515-1518 (1991).
Olney, J.W., et al, "Excitatory transmitter neurotoxicity and Alzheimer's disease," pp. 293-298 in Alzheimer Disease: Therapeutic Strategies (Giacobini & Becker, eds., Birkhauser Publ., Boston, 1994).
Olney, J.W., et al, "NMDA receptor hypofunction, excitotoxicity, and Alzheimer's disease," Neurobiology of Aging 16: 459-461 (1995).
Olney, J.W., et al, "Glutamate receptor dysfunction and schizophrenia," Arch. Gen. Psychiatry 52: 998-1007 (1995).
Olney, J. et al, "NMDA receptor dysfunction in Alzheimer's disease," pp. 107-112 in Alzheimer Disease: From Molecular Biology to Therapy (Becker & Giacobini, eds., Birkhauser Publ., Boston, 1996).
Schehr, R.S., "Therapeutic approaches to Alzheimer's disease," Bio/Technology 12: 140-144 (1994).
Selkoe, D.J., "Alzheimer's disease: Genotypes, phenotype, and treatments," Science 275: 630-631 (1997).
Farber Nuri B.
Olney John W.
Kelly Patrick D.
Spivack Phyllis G.
Washington University
LandOfFree
Preventing neuronal degeneration in Alzheimer's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preventing neuronal degeneration in Alzheimer's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preventing neuronal degeneration in Alzheimer's disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-423085